Article
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease.
Proteins - 15 Feb 2008
Altman Michael D, Nalivaika Ellen A, Prabu-Jeyabalan Moses, Schiffer Celia A, Tidor Bruce
Abstract excerpt
Drug resistance in HIV-1 protease, a barrier to effective treatment, is generally caused by mutations in the enzyme that disrupt inhibitor binding but still allow for substrate processing. Structural studies with mutant, inactive enzyme, have provided detailed information regarding how the substrates bind to the protease yet avoid resistance mutations; insights obtained inform the development of next generation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
